ARA 290 Research Material
For Research Use Only - Not for Human Consumption.
ARA 290 peptide product details matter when a study requires identity, lot traceability, and analytical documentation rather than broad marketing language. ARA 290 is an erythropoietin-derived research peptide used in controlled laboratory investigations of receptor-associated signaling, cell-based assay behavior, and peptide stability. It is supplied solely as a research-grade material for laboratory use.
For Research Use Only - Not for Human Consumption. This material is not a drug, dietary supplement, food product, veterinary product, or material intended for diagnostic or therapeutic use.
Prepared by the Research Team at The Peptide Source.
> Compliance Notice
>
> For Research Use Only - Not for Human Consumption. ARA 290 must be handled only by qualified personnel in an appropriate research setting. It is not approved for human or animal use. Do not use this material for administration, ingestion, injection, or any purpose outside legitimate laboratory research.
Product Description and Core Specifications
ARA 290, also referred to in published literature as cibinetide, is a short synthetic peptide based on the helix B region of erythropoietin. The commonly reported sequence is pGlu-Gln-Glu-Leu-Arg-Ala-Leu-Asn-Ser-Ser, often represented using one-letter notation as pQEQLERALNSS. The N-terminal pyroglutamate residue is part of the defined peptide identity and should be considered during analytical review.
The approximate molecular weight is 1,258.4 g/mol, subject to the counterion form and the specific analytical reporting convention used for a lot. Researchers should verify the exact mass, net peptide content, and chromatographic profile against the batch-specific certificate of analysis before initiating an experiment.
A research-grade ARA 290 product record should clearly identify the vial quantity, lot number, sequence, molecular weight, purity method, storage condition, and COA status. Peptide Source quality expectations center on a stated greater than 99% HPLC purity standard, supported by manufacturer documentation and additional third-party verification where available. Purity percentage alone is not sufficient for method development or comparative work. Retention time, chromatogram shape, mass confirmation, and lot-level records also matter.
For Research Use Only - Not for Human Consumption.
What Researchers Should Verify Before Use
For experienced buyers, the practical question is not simply whether a vial is labeled ARA 290. It is whether the material can be traced and evaluated within the study record. The first review point is the certificate of analysis. Confirm that the COA corresponds to the exact lot received, not a generic or representative batch.
The second review point is the analytical method. Reversed-phase HPLC is commonly used to assess peptide purity, while LC-MS or an equivalent mass-spectrometric method supports identity confirmation. A high reported HPLC area percentage can indicate a clean chromatographic profile, but it does not independently establish sequence identity, peptide content, or freedom from every possible process-related impurity. Those distinctions should be reflected in the experimental plan.
The third review point is material condition at receipt. Document vial labeling, package integrity, shipping date, storage transfer, and any visible irregularity before placing the material into inventory. For comparative assays, maintain lot consistency whenever possible. If a lot transition is unavoidable, bridge the lots with a predefined analytical or functional comparability check.
Storage and Laboratory Handling
Lyophilized peptides are generally stored under cool, dry, light-protected conditions consistent with the product label and batch documentation. Avoid unnecessary temperature cycling and extended exposure to ambient moisture. Once a laboratory has prepared an aliquot or solution for an approved in vitro workflow, storage conditions, solvent compatibility, concentration, container type, and hold time should be established by that laboratory's own stability protocol.
There is no universal solvent or storage interval that fits every assay design. It depends on concentration, buffer composition, pH, temperature, analytical endpoint, and the risk tolerance of the method. Researchers should assess solubility and solution stability in a small-scale, documented pilot before committing limited material to a larger study.
Research Context for ARA 290
ARA 290 is associated with research into the tissue-protective signaling framework described for erythropoietin-derived peptides. Published work has examined how selected erythropoietin domains can be separated from erythropoietic receptor activity in experimental systems. This distinction is one reason the peptide remains relevant as a laboratory tool for receptor biology and signal-transduction research.
In laboratory models, investigators have examined receptor-associated pathways that may involve the heteromeric innate repair receptor concept, often described in the literature in relation to erythropoietin receptor and CD131-associated signaling. Experimental interpretation requires caution. Receptor expression, species, cell type, assay timing, and peptide preparation can all change the observed readout.
A foundational publication by Brines and colleagues discussed nonerythropoietic peptide activity within this research area: Proceedings of the National Academy of Sciences, 2008, DOI: 10.1073/pnas.0710866105. Broader background on erythropoietin signaling beyond hematopoiesis is discussed by Brines and Cerami, Nature Reviews Neuroscience, 2005, DOI: 10.1038/nrn1687. ARA 290-specific literature should be evaluated study by study, with particular attention to model selection, material characterization, controls, and endpoint definitions.
These publications are research references, not evidence of approved use or intended application. They do not change the status of ARA 290 as a research material.
Mechanistic Questions Suitable for Lab Study
Researchers investigating ARA 290 may use it as a defined peptide analyte in controlled experiments that examine receptor engagement hypotheses, downstream phosphorylation profiles, transcriptional response patterns, or assay-specific concentration-response behavior. Suitable work can include cell-free characterization, receptor-expression comparisons, immunoassay development, chromatographic method validation, and stability testing.
Mechanistic observations in one experimental model should not be generalized without replication. A receptor-associated signal can reflect peptide concentration, exposure duration, matrix effects, cell passage number, target abundance, or assay interference. Negative controls, vehicle controls, reference materials, and independent analytical confirmation are essential when assigning a result to the peptide itself.
COA, Purity, and Lot Verification
Batch-specific documentation should be available for review before use. A complete ARA 290 COA commonly includes lot identification, peptide name, sequence, stated purity, HPLC chromatogram, mass result, test date, and release decision. Where third-party verification is performed, the review package should distinguish external results from manufacturer-generated data.
For a material specified at greater than 99% HPLC purity, the relevant question is how the value was generated and whether the lot documentation supports reproducibility. Ask whether the chromatogram is batch-specific, whether the method is identified, and whether mass data align with the expected molecular weight. This documentation supports traceability, but it does not replace laboratory-specific qualification for a particular assay.
Peptide Source positions its research inventory around controlled-facility production, manufacturer COAs, third-party lab verification, and US-based fulfillment. Researchers should retain the COA and associated lot records with their raw data, sample inventory, and method notes.
For Research Use Only - Not for Human Consumption.
Frequently Asked Questions
Is ARA 290 intended for human or animal administration?
No. For Research Use Only - Not for Human Consumption. It is not intended for administration, ingestion, injection, clinical use, veterinary use, or any other non-research purpose.
What sequence should appear in ARA 290 documentation?
The commonly reported sequence is pGlu-Gln-Glu-Leu-Arg-Ala-Leu-Asn-Ser-Ser, or pQEQLERALNSS. Confirm the exact sequence notation and molecular-weight reporting on the batch COA.
What does greater than 99% HPLC purity mean?
It generally refers to the principal peak area reported by a specified HPLC method. It is a useful quality indicator, but it should be reviewed alongside mass confirmation, lot traceability, and the full chromatogram.
Should labs perform incoming verification?
That depends on the study's risk profile. For exploratory work, COA review and inventory documentation may be appropriate. For regulated, comparative, or high-value studies, an incoming identity or purity check may be justified.
How should ARA 290 be stored?
Follow the product label and batch-specific documentation. Keep the lyophilized material dry, protected from light, and within the specified storage range. Establish solution stability through the laboratory's own protocol.
Is a batch-specific COA necessary?
Yes. A batch-specific COA is central to lot traceability. It should match the vial lot number and provide the analytical information needed for material review.
What should be recorded in the study file?
Record supplier, product name, lot number, receipt date, storage history, COA review, preparation details, aliquot identifiers, and any internal analytical checks.
The value of ARA 290 in a research workflow begins with disciplined material control. Start with the sequence, confirm the lot, review the chromatogram and mass data, and let the assay determine the qualification standard required.